Nektar Therapeutics (NKTR) Operating Margin (2010 - 2026)
Nektar Therapeutics' (NKTR) quarterly Operating Margin came in at 359.58% in Q1 2026, up 6618.0% year-on-year from 5.35% in Q1 2025, and down 183.44% quarter-over-quarter from 126.86% in Q4 2025.
Nektar Therapeutics (NKTR) Operating Margin (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Operating Margin history runs 17 years deep, the most recent figure standing at 359.58% for Q1 2026.
- On a quarterly basis, Operating Margin rose 6618.0% year-over-year to 359.58% in Q1 2026; TTM through Mar 2026 was 241.98%, a 11097.0% decrease from a year earlier, with the FY2025 full-year figure at 253.66%, down 14678.0% from the prior year.
- Operating Margin eased to 359.58% in Q1 2026 per NKTR's latest filing, from 126.86% in the prior quarter.
- Across five years, Operating Margin topped out at 49.18% in Q4 2024 and bottomed at 708.07% in Q2 2022.
- The 5-year median for Operating Margin is 238.25% (2022), against an average of 283.32%.
- Across the five-year window, Operating Margin sank 31906 bps in 2022 and surged 46123 bps in 2023, its largest moves.
- Year by year, Operating Margin stood at 238.25% in 2022, then jumped by 41 bps to 140.3% in 2023, then jumped by 135 bps to 49.18% in 2024, then sank by 358 bps to 126.86% in 2025, then slumped by 183 bps to 359.58% in 2026.
- Per Business Quant, the three latest NKTR Operating Margin figures stand at 359.58% (Q1 2026), 126.86% (Q4 2025), and 268.63% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Nektar Therapeutics | 2.04 Bn | 1.48 Bn | 3.16 Mn | -359.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -359.58% |
| Dec 31, 2025 | -126.86% |
| Sep 30, 2025 | -268.63% |
| Jun 30, 2025 | -324.21% |
| Mar 31, 2025 | -425.76% |
| Dec 31, 2024 | 49.18% |
| Sep 30, 2024 | -142.37% |
| Jun 30, 2024 | -211.90% |
| Mar 31, 2024 | -163.72% |
| Dec 31, 2023 | -140.30% |
| Sep 30, 2023 | -185.82% |
| Jun 30, 2023 | -246.84% |
| Mar 31, 2023 | -623.83% |
| Dec 31, 2022 | -238.25% |
| Sep 30, 2022 | -229.85% |
| Jun 30, 2022 | -708.07% |
| Mar 31, 2022 | -469.58% |
| Dec 31, 2021 | -451.48% |
| Sep 30, 2021 | -455.82% |
| Jun 30, 2021 | -389.00% |